In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh welcomes Dr Carl Marci, chief psychiatrist and managing director of mental health and neuroscience at OM1 to discuss
A proposed order by the Federal Trade Commission (FTC) would impose a $7 million fine on telehealth company Cerebral in connection with charges that it disclosed its custo
Shares in Intra-Cellular Therapies rose sharply after it reported that its only product Caplyta was effective for a new indication, major depressive disorder (MDD), in a p
Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that
Three digital health technologies (DHTs) used to support patients with psychosis can be used by the NHS while additional evidence of their benefits is gathered.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.